** Shares of U.S. drug distributor McKesson MCK.N rise about 6.8% to all-time high of $744.17
** MCK raises its fiscal 2026 profit forecast, saying it is expanding its focus on high-margin areas like cancer drug services to drive growth
** Now expects fiscal 2026 adjusted earnings to range between $38.05 and $38.55 per share, vs previous forecast of $37.10 to $37.90
** Co also lifts its long-term adjusted earnings growth target to 13% to 16%, from a prior range of 12% to 14%
** Including session's moves, stock up 22.3% YTD
(Reporting by Sanskriti Shekhar)
((Sanskriti.Shekhar@thomsonreuters.com))